Phase 3 Readout
MRNA: Phase 3 Topline: A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Re
July 24, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 24, 2026
- Company
- Moderna, Inc. (MRNA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Re
- Company
- Moderna, Inc. (MRNA)
- Indication
- Respiratory Syncytial Virus